neratinib
Selected indexed studies
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. (Clin Breast Cancer, 2021) [PMID:33183970]
- Neratinib for HER2-positive breast cancer with an overlooked option. (Mol Med, 2023) [PMID:37803271]
- Neratinib. (, 2012) [PMID:31644242]
_Worker-drafted node — pending editorial review._
Connections
neratinib is a side effect of
Sources
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. (2021) pubmed
- Neratinib for HER2-positive breast cancer with an overlooked option. (2023) pubmed
- Neratinib. (2012) pubmed
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) pubmed
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2016) pubmed
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. (2023) pubmed
- Neratinib: First Global Approval. (2017) pubmed
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. (2020) pubmed
- Neratinib for breast cancer. (2019) pubmed
- Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. (2020) pubmed